Recursion Pharmaceuticals (RXRX), a clinical-stage biotechnology company industrializing drug discovery by decoding biology has added Ryan Kelly as Chief Communications Officer where he will be responsible for external and internal communications. Mr. Kelly previously served as Vice President, Global Marketing and Communications at Virgin Hyperloop where he supported commercializing the company’s technology through global strategic communication campaigns. SEE FULL PRESS RELEASE HERE
Tenpoint Therapeutics, a clinical-stage cell therapy targeting unmet needs in ocular diseases, has added Kali Stasi, M.D., Ph.D., as its Senior Vice President of Clinical Development.
Previously, Kali served as a Translational Medicine Director at the Novartis Institutes for Biomedical Research, where she served as a clinical development leader for cell & gene therapy products programs pertaining to front- and back-of-the-eye indications. Prior to Novartis, Kali served as a professor & researcher at the University of Pennsylvania.
Kali Stasi earned her M.D. and Ph.D from the University of Patras, in Greece. She completed residencies at The Massachusetts Eye & Ear Infirmary, Mount Sinai Hospital, Johns Hopkins Hospital, and the Albert Einstein College of Medicine.
Occam is pleased to announce that Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, has appointed Rabia Gurses Ozden, M.D. to its Board of Directors.
Rabia currently serves as the Senior Vice President of Clinical Development at Ocular Therapeutix, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. Prior to joining Ocular Therapeutix, Rabia served as the Chief Development Officer at Akouos, leveraging their adeno-associated virus (AAV)-based gene therapy platform to advance precision therapies for forms of sensorineural hearing loss. Prior to joining Akouos, Rabia served as the Chief Medical Officer at Nightstar Therapeutics, an ocular gene therapy company focused on AAV treatments for inherited retinal diseases, which was acquired by Biogen in 2019. Additionally, Rabia has held leadership positions at Applied Genetic Technologies and GlaxoSmithKline, while spending her early career in clinical development roles. Rabia earned her M.D. from Hacettepe University School of Medicine, completed her ophthalmology residency at Ankara University School of Medicine, and her clinical fellowship in Glaucoma at the New York Eye and Ear Infirmary.
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, has brought on Craig Thompson as Chief Executive Officer. Craig brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
Craig recently served as President and CEO at Neurana Pharmaceuticals, a private company focused on the treatment of neuromuscular conditions. Prior to Neurana, he served as President and CEO of Anthera Pharmaceuticals, and before that, as Chief Operating Officer of Tetraphase Pharmaceuticals, where he oversaw the development and implementation of the marketing, access, reimbursement and sales strategy, as well as business development and commercial manufacturing. Prior to Tetraphase, he was Chief Commercial Officer for Trius Therapeutics, which was acquired by Cubist Pharmaceuticals for more than $700 million. Earlier in his career, Craig served in various commercial and marketing roles of increasing responsibility at Pfizer and Merck. He holds a Bachelor of Commerce degree from McMaster University and an M.B.A. from the University of Notre Dame. See Full Press Release HERE
Lycia Therapeutics, Inc., a leader in extracellular protein degradation has appointed Steve Staben, Ph.D., as Chief Scientific Officer. Prior to joining Lycia, Dr. Staben spent over 14 years at Genentech leading drug discovery programs in oncology and immunology as well as new modality platforms.
Steve has co–authored over 70 peer–reviewed articles and patent applications and holds his Ph.D. in organic chemistry from the University of California, Berkeley.
"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."Find out more Read the Case Study
"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."Find out more
"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."Find out more
"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."Find out more
“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”Find out more
Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.
Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.
The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.
Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.
Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.
Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.View all news